Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedinotecMDNC 24 3-Year ROIIC % is 74.64 as of Feb. 2026, which is at its 10-year median of 74.64. GuruFocus rates MDNC with a GF Score™ of 24/100. The stock has 1 warning sign investors should review.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Medinotec's 3-Year ROIIC % for the quarter that ended in Feb. 2026 was 74.64%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Medinotec's 3-Year ROIIC % or its related term are showing as below:
MDNC's 3-Year ROIIC % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.62
vs MDNC: 74.64
Medinotec (OTCPK:MDNC) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Medinotec 3-Year ROIIC % Related Terms
Medinotec 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Medinotec's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDNC vs NVNO, APYX, RDGL: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Medinotec's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinotec 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medinotec's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Medinotec's 3-Year ROIIC % falls into.
Medinotec's 3-Year ROIIC % for the quarter that ended in Feb. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 0.813366 (Feb. 2026) - -0.2151717 (Feb. 2023) )
/
( 2.97 (Feb. 2026) - 1.592 (Feb. 2023) )
=
1.0285377
/
1.378
=
74.64%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Medinotec (MDNC) has a 3-Year ROIIC % of 74.64 as of Feb. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medinotec and its competitors. This is near median its historical median of 74.64. Over the past decade, Medinotec's 3-Year ROIIC % has ranged from 74.64 to 74.64.
Is Medinotec's 3-Year ROIIC % too high?
Medinotec's current 3-Year ROIIC % of 74.64 is near median its 10-year median of 74.64. Over the past 10 years, this metric has ranged from a low of 74.64 to a high of 74.64. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.62. Medinotec's value of 74.64 is 4507.4% above this industry median. Overall, Medinotec has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Medinotec's 3-Year ROIIC % compare to NVNO and APYX?
Medinotec's 3-Year ROIIC % of 74.64 can be compared against companies in the Medical Devices & Instruments industry. The industry median 3-Year ROIIC % is 1.62. Medinotec's value of 74.64 is 4507.4% above this benchmark. Historically, Medinotec's own 3-Year ROIIC % has ranged from 74.64 to 74.64 over the past decade. While the company's 10-year median is 74.64 vs. the industry median of 1.62, Medinotec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.62, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinotec's current 3-Year ROIIC % of 74.64 is 4507.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Medinotec and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinotec's current 3-Year ROIIC % is 74.64, which is near median its own 10-year median of 74.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinotec stock overvalued right now?
Medinotec (MDNC) has a current 3-Year ROIIC % of 74.64. The current 3-Year ROIIC % is 74.64, which is near median its 10-year median of 74.64 and 4507.4% above the Medical Devices & Instruments industry median of 1.62. Medinotec's overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Medinotec (MDNC), the current 3-Year ROIIC % is 74.64 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medinotec Inc is a medical device manufacturing and distribution company engaged in tracheal non-occlusive airway dilation technology and medical device design. It generates revenue from two sources: internally designed and manufactured medical devices and distribution of third-party medical products under exclusive or non-exclusive agreements in defined territories. Its products include the Trachealator, the Outflo Aortic Valve Dilation Balloon Catheter, and the Cape Cross family of PTCA balloon catheters. It also distributes a range of cardiology and renal dialysis products on behalf of multinational manufacturers, mainly in South Africa. Its segments are Inside the United States and Outside the United States, with Outside the United States generating maximum revenue.
24GF Score
Get the complete analysis for MDNC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDNC has been successfully added to your 
